• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    2/10/22 8:47:19 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    SC 13G/A 1 tv02283-zoetisinc.htm SCHEDULE 13G/A zoetisinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  Zoetis Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  98978V103

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  98978V103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    802,239

    7.  SOLE DISPOSITIVE POWER

    35,368,534

    8.  SHARED DISPOSITIVE POWER

    1,964,071

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    37,332,605

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.89%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Zoetis Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    10 Sylvan Way
    Parsippany, NJ 07054

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    98978V103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $ZTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    1/12/2024$195.00 → $215.00Buy
    Stifel
    12/19/2023$230.00Buy
    Jefferies
    12/7/2023$237.00Outperform
    Exane BNP Paribas
    9/6/2023$230.00Buy
    HSBC Securities
    7/12/2022$205.00Overweight
    Piper Sandler
    3/9/2022$232.00 → $208.00Neutral
    Citigroup
    More analyst ratings

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Executive Vice President Polzer Robert J

      4 - Zoetis Inc. (0001555280) (Issuer)

      4/7/25 4:55:24 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Vice President Sarbaugh Keith

      4 - Zoetis Inc. (0001555280) (Issuer)

      4/7/25 4:55:13 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Vice President Fuller Julie

      4 - Zoetis Inc. (0001555280) (Issuer)

      4/7/25 4:55:03 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

      For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

      1/13/22 10:26:13 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Announces First Quarter 2025 Results

      Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quarter 2025 Delivers 9% Organic Operational Growth in Revenue and 6% Organic Operational Growth in Adjusted Net Income for First Quarter 2025 Reports Adjusted Net Income of $662 Million, or Adjusted Diluted EPS of $1.48, for First Quarter 2025 Updates Full Year 2025 Revenue Guidance to $9.425 - $9.575 Billion to Reflect the Impact of Foreign Exchange and Maintains Guidance for Organic Operational Revenue Growth of 6% to 8% Updates Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income t

      5/6/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

      Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nu

      3/27/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Participate in Upcoming Investor Conferences

      Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. Bank of America Securities 2025 Animal Health Summit on Thursday, February 27, 2025 at 1:20 p.m. ET. Barclays Global Healthcare Conference on Tuesday, March 11, 2025 at 10:30 a.m. ET. Investors and other interested parties can access live audio webcasts of the presentations by visiting http://investor.zoetis.com/events-presentations. Replays will also be available on the Zoetis website at the conclusion of each event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind b

      2/20/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Zoetis with a new price target

      Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00

      12/2/24 7:04:18 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Zoetis with a new price target

      BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00

      7/25/24 6:48:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Zoetis with a new price target

      Stifel reiterated coverage of Zoetis with a rating of Buy and set a new price target of $215.00 from $195.00 previously

      1/12/24 8:18:04 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      2/13/24 5:17:36 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      1/26/24 11:49:41 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      2/9/23 11:37:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Zoetis Inc.

      10-Q - Zoetis Inc. (0001555280) (Filer)

      5/6/25 1:29:54 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Zoetis Inc. (0001555280) (Filer)

      5/6/25 7:03:35 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Zoetis Inc.

      DEFA14A - Zoetis Inc. (0001555280) (Filer)

      4/9/25 9:04:50 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Financials

    Live finance-specific insights

    See more
    • Zoetis Announces First Quarter 2025 Results

      Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quarter 2025 Delivers 9% Organic Operational Growth in Revenue and 6% Organic Operational Growth in Adjusted Net Income for First Quarter 2025 Reports Adjusted Net Income of $662 Million, or Adjusted Diluted EPS of $1.48, for First Quarter 2025 Updates Full Year 2025 Revenue Guidance to $9.425 - $9.575 Billion to Reflect the Impact of Foreign Exchange and Maintains Guidance for Organic Operational Revenue Growth of 6% to 8% Updates Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income t

      5/6/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

      Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nu

      3/27/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Reports Fourth Quarter and Full Year 2024 Results

      Reports Revenue of $2.3 Billion, Growing 5%, and Net Income of $581 Million, or $1.29 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis for Fourth Quarter 2024 Delivers 6% Operational Growth in Revenue and 9% Operational Growth in Adjusted Net Income for Fourth Quarter 2024 Delivers 9% Organic Operational Growth in Revenue for Fourth Quarter 2024 After Accounting for the Divestiture of the Medicated Feed Additive Product Portfolio, Certain Water Soluble Products and Related Assets Reports Adjusted Net Income of $632 Million, or Adjusted Diluted EPS of $1.40, for Fourth Quarter 2024 Reports Revenue of $9.3 Billion, Growing 8%, and Net Income of $2.5

      2/13/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

      New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu

      11/11/24 9:20:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

      Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand

      4/1/24 4:30:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Petco Love Announces Newest Board Members

      Animal welfare nonprofit bolsters board to better serve the needs of pet lovers nationally SAN ANTONIO, Nov. 14, 2023 /PRNewswire/ -- Petco Love welcomes new members to its board of directors, tapping a wide range of expertise to support its lifesaving mission. Petco Love is committed to shared social values and its diverse and inclusive board composition is a significant reflection of the unified values of its communities served nationwide. Since its founding more than 20 years ago, Petco Love excels as a leader and valued partner in animal welfare by creating a better world

      11/14/23 6:03:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care